51
|
Hummel S, Osanger A, Bajari TM, Balasubramani M, Halfter W, Nimpf J, Schneider WJ. Extracellular matrices of the avian ovarian follicle. Molecular characterization of chicken perlecan. J Biol Chem 2004; 279:23486-94. [PMID: 15016830 DOI: 10.1074/jbc.m312694200] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
In egg-laying species, such as the chicken, the mode of transport of lipoprotein particles from the capillary plasma to endocytic receptors on the oocyte surface is largely unknown. Here we show by molecular characterization that the large prominent heparan sulfate proteoglycan of extracellular matrices, termed perlecan or HSPG2 (the product of the hspg2 gene), is a component of ovarian follicles that may participate in this process. However, although normally a major HSPG of basement membranes or basal laminae, in chicken follicles, perlecan is absent from the membranous structure between the theca interna and granulosa cell layers, which to date has been considered a bona fide basement membrane. Rather, the protein is localized in the extracellular matrix of theca externa cells, which produce this HSPG. Furthermore, in chicken testes, perlecan is localized in the peritubular spaces but in less organized fashion than the classical basement membrane components, agrin and laminin. All five domains and structural hallmarks of chicken perlecan (4071 residues) have been conserved in its mammalian counterparts. We have produced the recombinant domain II (containing low density lipoprotein (LDL) receptor-like binding repeats) of chicken perlecan and demonstrate its capacity to bind LDL and very low density lipoprotein (VLDL), apolipoprotein B-containing lipoproteins ultimately destined for uptake into oocytes via members of the low density lipoprotein receptor family. Binding to perlecan heparan sulfate side chains may facilitate the interaction of lipoproteins with domain II. Based on the current results and on domain-domain interactions revealed by recent ultrastructural investigations of the LDL receptor, nidogen, and laminin (Rudenko, G., Henry, L., Henderson, K., Ichtchenko, K., Brown, M. S., Goldstein, J. L., and Deisenhofer, J. (2002) Science 298, 2353-2358 and Takagi, J., Yang, Y., Liu, J. H., Wang, J. H., and Springer, T. A. (2003) Nature 424, 969-974), we propose a novel role of perlecan in mediating plasma-to-oocyte surface transport of VLDL particles.
Collapse
Affiliation(s)
- Susanna Hummel
- Max F. Perutz Laboratories, University Departments at the Vienna Biocenter, Institute of Medical Biochemistry, Department of Molecular Genetics, Medical University of Vienna, A-1030 Vienna, Austria
| | | | | | | | | | | | | |
Collapse
|
52
|
Tran PK, Tran-Lundmark K, Soininen R, Tryggvason K, Thyberg J, Hedin U. Increased Intimal Hyperplasia and Smooth Muscle Cell Proliferation in Transgenic Mice With Heparan Sulfate–Deficient Perlecan. Circ Res 2004; 94:550-8. [PMID: 14739157 DOI: 10.1161/01.res.0000117772.86853.34] [Citation(s) in RCA: 72] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Smooth muscle cell (SMC) proliferation is a critical process in vascular disease. Heparan sulfate (HS) proteoglycans inhibit SMC growth, but the role of endogenous counterparts in the vessel wall in control of SMC function is not known in detail. Perlecan is the major HS proteoglycans in SMC basement membranes and in vessel wall extracellular matrix (ECM). In this study, transgenic mice with HS-deficient perlecan were analyzed with respect to vascular phenotype and intimal lesion formation. Furthermore, SMC cultures were established and characterized with respect to morphology, immunocytochemical features, proteoglycan synthesis, proliferative capacity, and ECM binding of basic fibroblast growth factor (FGF-2). In vitro, mutant SMCs formed basement membranes with perlecan core protein, but with decreased levels of HS, they showed diminished secretion of HS-containing perlecan into the medium and a defective ECM-binding capacity of FGF-2. In vitro, mutant SMCs showed increased proliferation compared with wild-type cells, and in vivo, enhanced SMC proliferation and intimal hyperplasia were observed after flow cessation of the carotid artery in mutant mice. The results indicate that the endogenous HS side-chains of perlecan contribute to SMC growth control both in vitro and during intimal hyperplasia, possibly by sequestering heparin-binding mitogens such as FGF-2.
Collapse
Affiliation(s)
- Phan-Kiet Tran
- Department of Surgical Sciences, Karolinska Hospital, SE-17176 Stockholm, Sweden.
| | | | | | | | | | | |
Collapse
|
53
|
Chou HT, Chen YT, Wu JY, Tsai FJ. Lack of association between perlecan gene intron 6 BamHI polymorphism and risk of mitral valve prolapse in Taiwan Chinese. JAPANESE HEART JOURNAL 2004; 45:109-18. [PMID: 14973356 DOI: 10.1536/jhj.45.109] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Abnormalities of proteoglycan, collagen, and elastic fibers were found in floppy mitral valves. Perlecan is one of the three major classes of heparan sulfate proteoglycans within the cardiovascular system. The role of perlecan genetic variant in mitral valve prolapse (MVP) has not been studied. We therefore performed a case-controlled study investigating the possible relation between the perlecan gene intron 6 BamHI polymorphism and MVP among the Chinese population in Taiwan. We studied 100 patients with MVP diagnosed by echocardiography and 100 age- and sex-matched normal control subjects. The perlecan gene intron 6 BamHI polymorphism was identified by polymerase chain reaction-based restriction analysis. There were no significant differences in either the genotype distribution or allelic frequencies between MVP cases and controls for perlecan gene intron 6 BamHI polymorphism (P = 0.20 and 0.76, respectively). Further categorization of the MVP patients into mild and severe subgroups also revealed no statistical difference from controls for perlecan gene intron 6 BamHI polymorphism. It is concluded that perlecan gene intron 6 BamHI polymorphism is not a suitable genetic marker of MVP in Taiwan Chinese.
Collapse
Affiliation(s)
- Hsiang-Tai Chou
- Division of Cardiology, Department of Medicine, China Medical College Hospital, Taichung, Tiawan
| | | | | | | |
Collapse
|
54
|
Maeda T, Inoue M, Koshiba S, Yabuki T, Aoki M, Nunokawa E, Seki E, Matsuda T, Motoda Y, Kobayashi A, Hiroyasu F, Shirouzu M, Terada T, Hayami N, Ishizuka Y, Shinya N, Tatsuguchi A, Yoshida M, Hirota H, Matsuo Y, Tani K, Arakawa T, Carninci P, Kawai J, Hayashizaki Y, Kigawa T, Yokoyama S. Solution structure of the SEA domain from the murine homologue of ovarian cancer antigen CA125 (MUC16). J Biol Chem 2004; 279:13174-82. [PMID: 14764598 DOI: 10.1074/jbc.m309417200] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Human CA125, encoded by the MUC16 gene, is an ovarian cancer antigen widely used for a serum assay. Its extracellular region consists of tandem repeats of SEA domains. In this study we determined the three-dimensional structure of the SEA domain from the murine MUC16 homologue using multidimensional NMR spectroscopy. The domain forms a unique alpha/beta sandwich fold composed of two alpha helices and four antiparallel beta strands and has a characteristic turn named the TY-turn between alpha1 and alpha2. The internal mobility of the main chain is low throughout the domain. The residues that form the hydrophobic core and the TY-turn are fully conserved in all SEA domain sequences, indicating that the fold is common in the family. Interestingly, no other residues are conserved throughout the family. Thus, the sequence alignment of the SEA domain family was refined on the basis of the three-dimensional structure, which allowed us to classify the SEA domains into several subfamilies. The residues on the surface differ between these subfamilies, suggesting that each subfamily has a different function. In the MUC16 SEA domains, the conserved surface residues, Asn-10, Thr-12, Arg-63, Asp-75, Asp-112, Ser-115, and Phe-117, are clustered on the beta sheet surface, which may be functionally important. The putative epitope (residues 58-77) for anti-MUC16 antibodies is located around the beta2 and beta3 strands. On the other hand the tissue tumor marker MUC1 has a SEA domain belonging to another subfamily, and its GSVVV motif for proteolytic cleavage is located in the short loop connecting beta2 and beta3.
Collapse
Affiliation(s)
- Takeshi Maeda
- RIKEN Genomic Sciences Center, 1-7-22 Suehiro-cho, Tsurumi, Yokohama 230-0045, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
55
|
Abstract
Perlecan is a major heparan sulfate proteoglycan (HSPG) of basement membranes (BMs) and connective tissues. The core protein of perlecan is divided into five domains based on sequence homology to other known proteins. Commonly, the N-terminal domain I of mammalian perlecan is substituted with three HS chains that can bind a number of matrix molecules, cytokines, and growth factors. Perlecan is essential for metazoan life, as shown by genetic manipulations of nematodes, insects, and mice. There are also known human mutations that can be lethal. In vertebrates, new functions of perlecan emerged with the acquisition of a closed vascular system and skeletal connective tissues. Many of perlecan's functions may be related to the binding and presentation of growth factors to high-affinity tyrosine kinase (TK) receptors. Data are accumulating, as discussed here, that similar growth factor-mediated processes may have unwanted promoting effects on tumor cell proliferation and tumor angiogenesis. Understanding of these attributes at the molecular level may offer opportunities for therapeutic intervention.
Collapse
Affiliation(s)
- Xinnong Jiang
- Department of Cell Biology, University of Alabama at Birmingham, Birmingham, Alabama, and Division of Biomedical Sciences, Faculty of Medicine, Imperial College of Science, Technology and Medicine, London, United Kingdom
| | - John R. Couchman
- Department of Cell Biology, University of Alabama at Birmingham, Birmingham, Alabama, and Division of Biomedical Sciences, Faculty of Medicine, Imperial College of Science, Technology and Medicine, London, United Kingdom
- Correspondence to: Dr. John R. Couchman, Div. of Biomedical Sciences, Sir Alexander Fleming Building, Imperial College of Science, Technology and Medicine, Exhibition Road, South Kensington, London SW7 2AZ, UK. E-mail:
| |
Collapse
|
56
|
Winzen U, Cole GJ, Halfter W. Agrin is a chimeric proteoglycan with the attachment sites for heparan sulfate/chondroitin sulfate located in two multiple serine-glycine clusters. J Biol Chem 2003; 278:30106-14. [PMID: 12773545 DOI: 10.1074/jbc.m212676200] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Agrin is a large extracellular matrix protein that plays a key role in the formation and maintenance of the vertebrate neuromuscular junction. The amino acid sequence of agrin encodes a protein with a molecular size of 220 kDa, whereas SDS-PAGE shows a diffuse band around 400 kDa. Further studies showed that agrin is highly glycosylated and belongs to the family of heparan sulfate proteoglycans. By expressing different protein fragments, we localized the glycosaminoglycan (GAG) attachment sites to two locations within the agrin molecule. One site that is located between the seventh and eight follistatin-like domain includes 3 closely spaced serine-glycine (SG) consensus sequences and carries exclusively heparan sulfate side chains. The second site is located further downstream in the centrally located serine-threonine-rich domain and contains a cluster of 4 closely packed SG consensus sequences. This site predominantly carries chondroitin sulfate side chains. Investigating the contribution of individual serines in GAG priming by site-directed mutagenesis showed that each serine of the two SG clusters has the potential to carry GAGs. In accordance with the mixed GAG glycosylation of agrin peptide fragments, it was found that recombinant and in vivo-derived full-length agrin are not exclusively heparan sulfate proteoglycans but also carry chondroitin sulfate side chains.
Collapse
Affiliation(s)
- Uwe Winzen
- Department of Neurobiology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA
| | | | | |
Collapse
|
57
|
Dong S, Cole GJ, Halfter W. Expression of collagen XVIII and localization of its glycosaminoglycan attachment sites. J Biol Chem 2003; 278:1700-7. [PMID: 12433925 DOI: 10.1074/jbc.m209276200] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Collagen XVIII is the only currently known collagen that carries heparan sulfate glycosaminoglycan side chains. The number and location of the glycosaminoglycan attachment sites in the core protein were determined by eukaryotic expression of full-length chick collagen XVIII and site-directed mutagenesis. Three Ser-Gly consensus sequences carrying glycosaminoglycan side chains were detected in the middle and N-terminal part of the core protein. One of the Ser-Gly consensus sequences carried a heparan sulfate side chain, and the remaining two had mixed chondroitin and heparan sulfate side chains; thus, recombinant collagen XVIII was a hybrid of heparan sulfate and chondroitin proteoglycan. In contrast, collagen XVIII from all chick tissues so far assayed have exclusively heparan sulfate side chains, indicating that the posttranslational modification of proteins expressed in vitro is not entirely identical to the processing that occurs in a living embryo. Incubating the various mutated collagen XVIIIs with retinal basement membranes showed that the heparan sulfate glycosaminoglycan side chains mediate the binding of collagen XVIII to basement membranes.
Collapse
Affiliation(s)
- Sucai Dong
- Department of Neurobiology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA
| | | | | |
Collapse
|
58
|
Rossi M, Morita H, Sormunen R, Airenne S, Kreivi M, Wang L, Fukai N, Olsen BR, Tryggvason K, Soininen R. Heparan sulfate chains of perlecan are indispensable in the lens capsule but not in the kidney. EMBO J 2003; 22:236-45. [PMID: 12514129 PMCID: PMC140094 DOI: 10.1093/emboj/cdg019] [Citation(s) in RCA: 188] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Mice lacking exon 3 of perlecan (Hspg2) gene were generated by gene targeting. Exon deletion does not alter the expression or the reading frame but causes loss of attachment sites for three heparan sulfate (HS) side chains. Hspg2(Delta 3 / Delta 3) mice are viable and fertile but have small eyes. Apoptosis and leakage of cellular material through the lens capsule are observed in neonatal lenses, and lenses degenerate within 3 weeks of birth. Electron microscopy revealed altered structure of the lens capsule through which cells had formed extensions. No kidney malfunction, such as protein uria, was detected in Hspg2(Delta 3 / Delta 3) mutant mice, nor were ultrastructural changes observed in the glomerular basement membranes (BMs). To achieve further depletion in the HS content of the BMs, Hspg2(Delta 3 / Delta 3) mice were bred with collagen XVIII null mice. Lens defects were more severe in the newborn Col18a1(-/-) x Hspg2(Delta 3 / Delta 3) mice and degeneration proceeded faster than in Hspg2(Delta 3 / Delta 3) mice. The results suggest that in the lens capsule, HS chains have a structural function and are essential in the insulation of the lens from its environment and in regulation of incoming signals.
Collapse
Affiliation(s)
- Maarit Rossi
- Biocenter Oulu,
Department of Medical Biochemistry and Molecular Biology, Department of Pathology, Department of Biochemistry, University of Oulu, FIN-90014 Oulu, Finland, Division of Matrix Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, S-171 77 Stockholm, Sweden and Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA Corresponding author e-mail:
| | - Hiroyuki Morita
- Biocenter Oulu,
Department of Medical Biochemistry and Molecular Biology, Department of Pathology, Department of Biochemistry, University of Oulu, FIN-90014 Oulu, Finland, Division of Matrix Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, S-171 77 Stockholm, Sweden and Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA Corresponding author e-mail:
| | - Raija Sormunen
- Biocenter Oulu,
Department of Medical Biochemistry and Molecular Biology, Department of Pathology, Department of Biochemistry, University of Oulu, FIN-90014 Oulu, Finland, Division of Matrix Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, S-171 77 Stockholm, Sweden and Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA Corresponding author e-mail:
| | - Sari Airenne
- Biocenter Oulu,
Department of Medical Biochemistry and Molecular Biology, Department of Pathology, Department of Biochemistry, University of Oulu, FIN-90014 Oulu, Finland, Division of Matrix Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, S-171 77 Stockholm, Sweden and Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA Corresponding author e-mail:
| | - Marjut Kreivi
- Biocenter Oulu,
Department of Medical Biochemistry and Molecular Biology, Department of Pathology, Department of Biochemistry, University of Oulu, FIN-90014 Oulu, Finland, Division of Matrix Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, S-171 77 Stockholm, Sweden and Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA Corresponding author e-mail:
| | - Ling Wang
- Biocenter Oulu,
Department of Medical Biochemistry and Molecular Biology, Department of Pathology, Department of Biochemistry, University of Oulu, FIN-90014 Oulu, Finland, Division of Matrix Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, S-171 77 Stockholm, Sweden and Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA Corresponding author e-mail:
| | - Naomi Fukai
- Biocenter Oulu,
Department of Medical Biochemistry and Molecular Biology, Department of Pathology, Department of Biochemistry, University of Oulu, FIN-90014 Oulu, Finland, Division of Matrix Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, S-171 77 Stockholm, Sweden and Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA Corresponding author e-mail:
| | - Bjorn R. Olsen
- Biocenter Oulu,
Department of Medical Biochemistry and Molecular Biology, Department of Pathology, Department of Biochemistry, University of Oulu, FIN-90014 Oulu, Finland, Division of Matrix Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, S-171 77 Stockholm, Sweden and Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA Corresponding author e-mail:
| | - Karl Tryggvason
- Biocenter Oulu,
Department of Medical Biochemistry and Molecular Biology, Department of Pathology, Department of Biochemistry, University of Oulu, FIN-90014 Oulu, Finland, Division of Matrix Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, S-171 77 Stockholm, Sweden and Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA Corresponding author e-mail:
| | - Raija Soininen
- Biocenter Oulu,
Department of Medical Biochemistry and Molecular Biology, Department of Pathology, Department of Biochemistry, University of Oulu, FIN-90014 Oulu, Finland, Division of Matrix Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, S-171 77 Stockholm, Sweden and Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA Corresponding author e-mail:
| |
Collapse
|
59
|
Abstract
Virtually every cell type in metazoan organisms produces heparan sulfate. These complex polysaccharides provide docking sites for numerous protein ligands and receptors involved in diverse biological processes, including growth control, signal transduction, cell adhesion, hemostasis, and lipid metabolism. The binding sites consist of relatively small tracts of variably sulfated glucosamine and uronic acid residues in specific arrangements. Their formation occurs in a tissue-specific fashion, generated by the action of a large family of enzymes involved in nucleotide sugar metabolism, polymer formation (glycosyltransferases), and chain processing (sulfotransferases and an epimerase). New insights into the specificity and organization of the biosynthetic apparatus have emerged from genetic studies of cultured cells, nematodes, fruit flies, zebrafish, rodents, and humans. This review covers recent developments in the field and provides a resource for investigators interested in the incredible diversity and specificity of this process.
Collapse
Affiliation(s)
- Jeffrey D Esko
- Department of Cellular and Molecular Medicine, Glycobiology Research and Training Center, University of California at San Diego, La Jolla, California, 92093-0687, USA.
| | | |
Collapse
|
60
|
Govindraj P, West L, Koob TJ, Neame P, Doege K, Hassell JR. Isolation and identification of the major heparan sulfate proteoglycans in the developing bovine rib growth plate. J Biol Chem 2002; 277:19461-9. [PMID: 11909863 DOI: 10.1074/jbc.m200786200] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Heparan sulfate proteoglycans are thought to mediate the action of growth factors. The heparan sulfate-containing proteoglycans in extracts of the bovine fetal rib growth plate were detected using the monoclonal antibody 3G10, which recognizes a neoepitope generated by heparitinase digestion (David, G., Bai, X. M., Van der Schueren, B., Cassiman, J. J., and Van den Berghe, H. (1992) J. Cell Biol. 119, 961-975). The heparan sulfate proteoglycans that react with this antibody were identified using antisera to known proteoglycans; purified using CsCl density gradient centrifugation, molecular sieve, and ion exchange chromatography; and then characterized. The major heparan sulfate proteoglycans in the growth plate had core proteins of 200 kDa and larger and were identified as perlecan and aggrecan. These two heparan sulfate proteoglycans could be effectively separated from each other by CsCl density gradient centrifugation alone. Perlecan contained 25% heparan sulfate and 75% chondroitin sulfate. The heparan sulfate chains on growth plate perlecan were considerably smaller than the chondroitin sulfate chains, and the heparan sulfate disaccharide content was different than that found for heparan sulfate from either kidney, tumor tissue, or growth plate aggrecan. Aggrecan contained only 0.1% heparan sulfate, which was localized to the CS-1 domain of aggrecan. These results indicate that perlecan and aggrecan would be the principal candidate proteoglycans involved in the action of heparan sulfate-binding proteins in the developing growth plate.
Collapse
Affiliation(s)
- Prasanthi Govindraj
- Center for Research in Skeletal Development and Pediatric Orthopedics, Shriners Hospital for Children, Tampa, Florida 33612, USA
| | | | | | | | | | | |
Collapse
|
61
|
Abstract
Perlecan, a large heparan sulfate proteoglycan (HSPG), is present in the basement membrane and other extracellular matrices. Its protein core is 400 kDa in size and consists of five distinct structural domains. A number of in vitro studies suggest multiple functions of perlecan in cell growth and differentiation and tissue organization. Recent studies with gene knockout mice and human diseases revealed critical in vivo roles of perlecan in cartilage development and neuromuscular junction activity.
Collapse
Affiliation(s)
- John Hassell
- The Center for Research in Skeletal Development and Pediatric Orthopaedics, Shriners Hospitals for Children, Tampa, FL 33612, USA.
| | | | | |
Collapse
|
62
|
Arikawa-Hirasawa E, Le AH, Nishino I, Nonaka I, Ho NC, Francomano CA, Govindraj P, Hassell JR, Devaney JM, Spranger J, Stevenson RE, Iannaccone S, Dalakas MC, Yamada Y. Structural and functional mutations of the perlecan gene cause Schwartz-Jampel syndrome, with myotonic myopathy and chondrodysplasia. Am J Hum Genet 2002; 70:1368-75. [PMID: 11941538 PMCID: PMC447613 DOI: 10.1086/340390] [Citation(s) in RCA: 137] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2001] [Accepted: 02/22/2002] [Indexed: 11/03/2022] Open
Abstract
Perlecan, a large heparan sulfate proteoglycan, is a component of the basement membrane and other extracellular matrices and has been implicated in multiple biological functions. Mutations in the perlecan gene (HSPG2) cause two classes of skeletal disorders: the relatively mild Schwartz-Jampel syndrome (SJS) and severe neonatal lethal dyssegmental dysplasia, Silverman-Handmaker type (DDSH). SJS is an autosomal recessive skeletal dysplasia characterized by varying degrees of myotonia and chondrodysplasia, and patients with SJS survive. The molecular mechanism underlying the chondrodystrophic myotonia phenotype of SJS is unknown. In the present report, we identify five different mutations that resulted in various forms of perlecan in three unrelated patients with SJS. Heterozygous mutations in two patients with SJS either produced truncated perlecan that lacked domain V or significantly reduced levels of wild-type perlecan. The third patient had a homozygous 7-kb deletion that resulted in reduced amounts of nearly full-length perlecan. Unlike DDSH, the SJS mutations result in different forms of perlecan in reduced levels that are secreted to the extracellular matrix and are likely partially functional. These findings suggest that perlecan has an important role in neuromuscular function and cartilage formation, and they define the molecular basis involved in the difference in the phenotypic severity between DDSH and SJS.
Collapse
Affiliation(s)
- Eri Arikawa-Hirasawa
- Craniofacial Developmental Biology and Regeneration Branch, National Institute of Dental and Craniofacial Research, and National Institute of Neuronal Disorders and Strokes, Bethesda; Department of Ultrastructural Research, National Institute of Neuroscience, Tokyo; Laboratory of Genetics, National Institute on Aging, and Johns Hopkins Bayview Medical Center, Baltimore; Shriners Hospital for Children, Tampa; Children's National Medical Center, Washington; Greenwood Genetic Center, Greenwood, SC; and Texas Scottish Rite Hospital, Dallas
| | - Alexander H. Le
- Craniofacial Developmental Biology and Regeneration Branch, National Institute of Dental and Craniofacial Research, and National Institute of Neuronal Disorders and Strokes, Bethesda; Department of Ultrastructural Research, National Institute of Neuroscience, Tokyo; Laboratory of Genetics, National Institute on Aging, and Johns Hopkins Bayview Medical Center, Baltimore; Shriners Hospital for Children, Tampa; Children's National Medical Center, Washington; Greenwood Genetic Center, Greenwood, SC; and Texas Scottish Rite Hospital, Dallas
| | - Ichizo Nishino
- Craniofacial Developmental Biology and Regeneration Branch, National Institute of Dental and Craniofacial Research, and National Institute of Neuronal Disorders and Strokes, Bethesda; Department of Ultrastructural Research, National Institute of Neuroscience, Tokyo; Laboratory of Genetics, National Institute on Aging, and Johns Hopkins Bayview Medical Center, Baltimore; Shriners Hospital for Children, Tampa; Children's National Medical Center, Washington; Greenwood Genetic Center, Greenwood, SC; and Texas Scottish Rite Hospital, Dallas
| | - Ikuya Nonaka
- Craniofacial Developmental Biology and Regeneration Branch, National Institute of Dental and Craniofacial Research, and National Institute of Neuronal Disorders and Strokes, Bethesda; Department of Ultrastructural Research, National Institute of Neuroscience, Tokyo; Laboratory of Genetics, National Institute on Aging, and Johns Hopkins Bayview Medical Center, Baltimore; Shriners Hospital for Children, Tampa; Children's National Medical Center, Washington; Greenwood Genetic Center, Greenwood, SC; and Texas Scottish Rite Hospital, Dallas
| | - Nicola C. Ho
- Craniofacial Developmental Biology and Regeneration Branch, National Institute of Dental and Craniofacial Research, and National Institute of Neuronal Disorders and Strokes, Bethesda; Department of Ultrastructural Research, National Institute of Neuroscience, Tokyo; Laboratory of Genetics, National Institute on Aging, and Johns Hopkins Bayview Medical Center, Baltimore; Shriners Hospital for Children, Tampa; Children's National Medical Center, Washington; Greenwood Genetic Center, Greenwood, SC; and Texas Scottish Rite Hospital, Dallas
| | - Clair A. Francomano
- Craniofacial Developmental Biology and Regeneration Branch, National Institute of Dental and Craniofacial Research, and National Institute of Neuronal Disorders and Strokes, Bethesda; Department of Ultrastructural Research, National Institute of Neuroscience, Tokyo; Laboratory of Genetics, National Institute on Aging, and Johns Hopkins Bayview Medical Center, Baltimore; Shriners Hospital for Children, Tampa; Children's National Medical Center, Washington; Greenwood Genetic Center, Greenwood, SC; and Texas Scottish Rite Hospital, Dallas
| | - Prasanthi Govindraj
- Craniofacial Developmental Biology and Regeneration Branch, National Institute of Dental and Craniofacial Research, and National Institute of Neuronal Disorders and Strokes, Bethesda; Department of Ultrastructural Research, National Institute of Neuroscience, Tokyo; Laboratory of Genetics, National Institute on Aging, and Johns Hopkins Bayview Medical Center, Baltimore; Shriners Hospital for Children, Tampa; Children's National Medical Center, Washington; Greenwood Genetic Center, Greenwood, SC; and Texas Scottish Rite Hospital, Dallas
| | - John R. Hassell
- Craniofacial Developmental Biology and Regeneration Branch, National Institute of Dental and Craniofacial Research, and National Institute of Neuronal Disorders and Strokes, Bethesda; Department of Ultrastructural Research, National Institute of Neuroscience, Tokyo; Laboratory of Genetics, National Institute on Aging, and Johns Hopkins Bayview Medical Center, Baltimore; Shriners Hospital for Children, Tampa; Children's National Medical Center, Washington; Greenwood Genetic Center, Greenwood, SC; and Texas Scottish Rite Hospital, Dallas
| | - Joseph M. Devaney
- Craniofacial Developmental Biology and Regeneration Branch, National Institute of Dental and Craniofacial Research, and National Institute of Neuronal Disorders and Strokes, Bethesda; Department of Ultrastructural Research, National Institute of Neuroscience, Tokyo; Laboratory of Genetics, National Institute on Aging, and Johns Hopkins Bayview Medical Center, Baltimore; Shriners Hospital for Children, Tampa; Children's National Medical Center, Washington; Greenwood Genetic Center, Greenwood, SC; and Texas Scottish Rite Hospital, Dallas
| | - Jürgen Spranger
- Craniofacial Developmental Biology and Regeneration Branch, National Institute of Dental and Craniofacial Research, and National Institute of Neuronal Disorders and Strokes, Bethesda; Department of Ultrastructural Research, National Institute of Neuroscience, Tokyo; Laboratory of Genetics, National Institute on Aging, and Johns Hopkins Bayview Medical Center, Baltimore; Shriners Hospital for Children, Tampa; Children's National Medical Center, Washington; Greenwood Genetic Center, Greenwood, SC; and Texas Scottish Rite Hospital, Dallas
| | - Roger E. Stevenson
- Craniofacial Developmental Biology and Regeneration Branch, National Institute of Dental and Craniofacial Research, and National Institute of Neuronal Disorders and Strokes, Bethesda; Department of Ultrastructural Research, National Institute of Neuroscience, Tokyo; Laboratory of Genetics, National Institute on Aging, and Johns Hopkins Bayview Medical Center, Baltimore; Shriners Hospital for Children, Tampa; Children's National Medical Center, Washington; Greenwood Genetic Center, Greenwood, SC; and Texas Scottish Rite Hospital, Dallas
| | - Susan Iannaccone
- Craniofacial Developmental Biology and Regeneration Branch, National Institute of Dental and Craniofacial Research, and National Institute of Neuronal Disorders and Strokes, Bethesda; Department of Ultrastructural Research, National Institute of Neuroscience, Tokyo; Laboratory of Genetics, National Institute on Aging, and Johns Hopkins Bayview Medical Center, Baltimore; Shriners Hospital for Children, Tampa; Children's National Medical Center, Washington; Greenwood Genetic Center, Greenwood, SC; and Texas Scottish Rite Hospital, Dallas
| | - Marinos C. Dalakas
- Craniofacial Developmental Biology and Regeneration Branch, National Institute of Dental and Craniofacial Research, and National Institute of Neuronal Disorders and Strokes, Bethesda; Department of Ultrastructural Research, National Institute of Neuroscience, Tokyo; Laboratory of Genetics, National Institute on Aging, and Johns Hopkins Bayview Medical Center, Baltimore; Shriners Hospital for Children, Tampa; Children's National Medical Center, Washington; Greenwood Genetic Center, Greenwood, SC; and Texas Scottish Rite Hospital, Dallas
| | - Yoshihiko Yamada
- Craniofacial Developmental Biology and Regeneration Branch, National Institute of Dental and Craniofacial Research, and National Institute of Neuronal Disorders and Strokes, Bethesda; Department of Ultrastructural Research, National Institute of Neuroscience, Tokyo; Laboratory of Genetics, National Institute on Aging, and Johns Hopkins Bayview Medical Center, Baltimore; Shriners Hospital for Children, Tampa; Children's National Medical Center, Washington; Greenwood Genetic Center, Greenwood, SC; and Texas Scottish Rite Hospital, Dallas
| |
Collapse
|
63
|
Sasaki T, Mann K, Miner JH, Miosge N, Timpl R. Domain IV of mouse laminin beta1 and beta2 chains. EUROPEAN JOURNAL OF BIOCHEMISTRY 2002; 269:431-42. [PMID: 11856301 DOI: 10.1046/j.0014-2956.2001.02663.x] [Citation(s) in RCA: 61] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Domain IV, consisting of about 230 residues, represents a particular protein module so far found only in laminin beta1 and beta2 chains. Both domains were obtained by recombinant production in mammalian cells. They showed a globular structure, as expected from electron microscopic examination of laminins. Fragment beta1IV was obtained as a monomer and a disulfide-bonded dimer, and both were modified to approximately 50% by a single chondroitin sulfate chain attached to Ser721 of an SGD consensus sequence. Dimerization is caused by an odd number of cysteines, with three of them having a partial thiol character. Whether both modifications also occur in tissue forms of laminin remains to be established. Fragment beta2IV was only obtained as a monomer, as it lacked one crucial cysteine and the SGD sequence. It required, however, the presence of two adjacent LE modules for proper folding. Polyclonal antibodies raised against both fragments showed no cross-reaction with each other and allowed establishment of beta chain-specific radioimmunoassays and light and electron microscopic immunostaining of tissues. This demonstrated a 5-25-fold lower content of beta2 compared with beta1 chains in various tissue extracts of adult mice. Tissues derived from beta2-deficient mice failed to react with the beta2-specific antibodies but showed a twofold higher content of beta1 than heterozygotes. The antibodies to beta2 showed broader tissue staining than reported previously, including in particular a distinct reaction with the extrasynaptic endomysium of skeletal muscle. Immunogold staining localized both beta chains primarily to basement membranes of kidney, muscle and various other tissues.
Collapse
Affiliation(s)
- Takako Sasaki
- Max-Planck-Institut für Biochemie, Martinsried, Germany
| | | | | | | | | |
Collapse
|
64
|
Ghiselli G, Eichstetter I, Iozzo RV. A role for the perlecan protein core in the activation of the keratinocyte growth factor receptor. Biochem J 2001; 359:153-63. [PMID: 11563979 PMCID: PMC1222131 DOI: 10.1042/0264-6021:3590153] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Perlecan, a widespread heparan sulphate (HS) proteoglycan, is directly involved in the storing of angiogenic growth factors, mostly members of the fibroblast growth factor (FGF) gene family. We have previously shown that antisense targeting of the perlecan gene causes a reduced growth and responsiveness to FGF7 [also known as keratinocyte growth factor (KGF)] in human cancer cells, and that the perlecan protein core interacts specifically with FGF7. In the present paper, we have investigated human colon carcinoma cells in which the perlecan gene was disrupted by targeted homologous recombination. After screening over 1000 clones, we obtained two clones heterozygous for the null mutation with no detectable perlecan, indicating that the other allele was non-functioning. The perlecan-deficient cells grew more slowly, did not respond to FGF7 with or without the addition of heparin, and were less tumorigenic than control cells. Paradoxically, the perlecan-deficient cells displayed increased FGF7 surface binding. However, the perlecan protein core was required for functional activation of the KGF receptor and downstream signalling. Because heparin could not substitute for perlecan, the HS chains are not critical for FGF7-mediated signalling in this cell system. These results provide the first genetic evidence that the perlecan protein core is a molecular entity implicated in FGF7 binding and activation of its receptor.
Collapse
MESH Headings
- Animals
- Blotting, Northern
- Blotting, Western
- Cell Division/drug effects
- Colonic Neoplasms/metabolism
- DNA, Antisense/pharmacology
- Fibrinolytic Agents/pharmacology
- Fibroblast Growth Factor 1/metabolism
- Fibroblast Growth Factor 7
- Fibroblast Growth Factors/metabolism
- Gene Targeting
- Heparan Sulfate Proteoglycans/physiology
- Heparin/pharmacology
- Humans
- Mice
- Mice, Nude
- Neoplasms, Experimental/metabolism
- Neoplasms, Experimental/pathology
- Protein Binding
- Receptor, Fibroblast Growth Factor, Type 2
- Receptors, Fibroblast Growth Factor/metabolism
- Recombinant Proteins/metabolism
- Signal Transduction
- Transplantation, Heterologous
- Tumor Cells, Cultured/drug effects
- Tumor Cells, Cultured/metabolism
- Tumor Cells, Cultured/transplantation
Collapse
Affiliation(s)
- G Ghiselli
- Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, 1020 Locust Street, Philadelphia, PA 19107, USA
| | | | | |
Collapse
|
65
|
Sasaki T, Mann K, Timpl R. Modification of the laminin alpha 4 chain by chondroitin sulfate attachment to its N-terminal domain. FEBS Lett 2001; 505:173-8. [PMID: 11557064 DOI: 10.1016/s0014-5793(01)02812-5] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The N-terminal domain of laminin alpha 4 chains corresponds to a short rod-like structure which after recombinant production was found to be modified by chondroitin sulfate. Substitution occurred mainly to a single serine in its N-terminal ASGDG sequence. A similar yet partial modification was also demonstrated for the alpha 4 chain present in extracts of adult mouse tissues. Antibodies to the fragment were useful to demonstrate a relatively high content of alpha 4 in several tissues and for the immunolocalization in various blood vessels, some basement membranes and interstitial regions.
Collapse
Affiliation(s)
- T Sasaki
- Max-Planck-Institut für Biochemie, Am Klopferspitz 18A, D-82152 Martinsried, Germany.
| | | | | |
Collapse
|
66
|
Ueno M, Yamada S, Zako M, Bernfield M, Sugahara K. Structural characterization of heparan sulfate and chondroitin sulfate of syndecan-1 purified from normal murine mammary gland epithelial cells. Common phosphorylation of xylose and differential sulfation of galactose in the protein linkage region tetrasaccharide sequence. J Biol Chem 2001; 276:29134-40. [PMID: 11384972 DOI: 10.1074/jbc.m102089200] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Syndecan-1, present on the surfaces of normal murine mammary gland epithelial cells, is a transmembrane hybrid proteoglycan, which bears glycosaminoglycan (GAG) side chains of heparan sulfate (HS) and chondroitin sulfate (CS). Purified syndecan-1 ectodomains were analyzed for disaccharide composition and the GAG-protein linkage region after digestion with bacterial lyases. The HS chains contained predominantly a nonsulfated unit with smaller proportions of two monosulfated, two disulfated, and a trisulfated unit, whereas CS chains were demonstrated for the first time to bear GlcUA-GalNAc(4-O-sulfate) as a major component as well as GlcUA-GalNAc, GlcUA-GalNAc(6-O-sulfate), and an E disaccharide unit GlcUA-GalNAc(4,6-O-disulfate) as minor yet appreciable components. Two kinds of linkage region tetrasaccharides, GlcUA-Gal-Gal-Xyl and GlcUA-Gal-Gal-Xyl(2-O-phosphate), were found for the HS chains in a molar ratio of 55:45. In marked contrast, an additional sulfated tetrasaccharide, GlcUA-Gal(4-O-sulfate)-Gal-Xyl, was demonstrated only for the CS chains, and the unmodified phosphorylated and sulfated components were present at a molar ratio of 55:26:19. The present study thus provided conclusive evidence for the hypothesis that 4-O-sulfation of Gal is peculiar to CS chains in contrast to the phosphorylation of Xyl, which is common to both HS and CS chains. These modifications may be required for biosynthetic maturation of the linkage region tetrasaccharide sequence, which is a prerequisite for creating the repeating disaccharide region of GAG chains and/or biosynthetic selective chain assembly of CS and HS chains.
Collapse
Affiliation(s)
- M Ueno
- Department of Biochemistry, Kobe Pharmaceutical University, Higashinada-ku, Kobe 658-8558, Japan
| | | | | | | | | |
Collapse
|
67
|
Delehedde M, Lyon M, Sergeant N, Rahmoune H, Fernig DG. Proteoglycans: pericellular and cell surface multireceptors that integrate external stimuli in the mammary gland. J Mammary Gland Biol Neoplasia 2001; 6:253-73. [PMID: 11547896 DOI: 10.1023/a:1011367423085] [Citation(s) in RCA: 62] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Proteoglycans consist of a core protein and an associated glycosaminoglycan (GAG) chain of heparan sulfate, chondroitin sulfate, dermatan sulfate or keratan sulfate, which are attached to a serine residue. The core proteins of cell surface proteoglycans may be transmembrane, e.g., syndecan, or GPI-anchored, e.g., glypican. Many different cell surface and matrix proteoglycan core proteins are expressed in the mammary gland and in mammary cells in culture. The level of expression of these core proteins, the structure of their GAG chains, and their degradation are regulated by many of the effectors that control the development and function of the mammary gland. Regulatory proteins of the mammary gland that bind GAG include many growth factors and morphogens (fibroblast growth factors, hepatocyte growth factor/scatter factor, members of the midkine family, wnts), matrix proteins (collagen, fibronectin, and laminin), enzymes (lipoprotein lipase) and microbial surface proteins. Structural diversity within GAG chains ensures that each protein-GAG interaction is as specific as necessary and a number of sequences of saccharides that recognize individual proteins have been elucidated. The GAG-protein interactions serve to regulate the signal output of growth factor receptor tyrosine kinase and hence cell fate as well as the storage and diffusion of extracellular protein effectors. In addition, GAGs clearly coordinate stromal and epithelial development, and they are active participants in mediating cell-cell and cell-matrix interactions. Since a single proteoglycan, even if it carries a single GAG chain, can bind multiple proteins, proteoglycans are also likely to act as multireceptors which promote the integration of cellular signals.
Collapse
Affiliation(s)
- M Delehedde
- School of Biological Sciences, University of Liverpool, United Kingdom
| | | | | | | | | |
Collapse
|
68
|
Hart M, Li L, Tokunaga T, Lindsey JR, Hassell JR, Snow AD, Fukuchi K. Overproduction of perlecan core protein in cultured cells and transgenic mice. J Pathol 2001; 194:262-9. [PMID: 11400157 DOI: 10.1002/1096-9896(200106)194:2<262::aid-path882>3.0.co;2-w] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Heparan sulphate proteoglycan (HSPG) and amyloid P component are the only macromolecules consistently associated with all varieties of amyloid, irrespective of the type of amyloid protein, suggesting that HSPG may play a pathogenetic role in amyloid formation through a common mechanism. In the case of Alzheimer's disease (AD), HSPG, such as perlecan, co-accumulates with amyloid-beta protein (Abeta), a main constituent of amyloid plaques, and paired helical filaments (PHFs). Additionally, in vitro, HSPG accelerates both Abeta fibril and PHF formation and protects Abeta from degradation. Therefore, this study first established lines of P19 mouse embryonic carcinoma cells stably carrying an expression vector encoding the complete perlecan core protein (approximately 400 kD). In the cell lysates, overexpressed perlecan was identified as an approximately 400 kD protein without glycosaminoglycan side-chains, while in the media, secreted perlecan was mostly glycosylated, suggesting that the secretion and glycosylation of perlecan are coupled. Next, transgenic mice were produced using the same expression vector. Marked perlecan overexpression occurred in the cytoplasm of multiple tissues including the brain, heart, kidney, and pancreas, without a discernible increase of perlecan in extracellular matrices. The transgenic mice up to 18 months of age did not develop amyloid or AD-like pathology in the brain or elsewhere, based on histochemical and immunohistochemical analyses. Thus, overproduction of perlecan core protein is insufficient to lead to amyloidosis and AD-like pathology.
Collapse
Affiliation(s)
- M Hart
- Department of Comparative Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
| | | | | | | | | | | | | |
Collapse
|
69
|
Kresse H, Seidler DG, Muller M, Breuer E, Hausser H, Roughley PJ, Schonherr E. Different usage of the glycosaminoglycan attachment sites of biglycan. J Biol Chem 2001; 276:13411-6. [PMID: 11145959 DOI: 10.1074/jbc.m009321200] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Biglycan is a member of the small leucine-rich proteoglycan family. Its core protein comprises two chondroitin/dermatan sulfate attachment sites on serine 42 and serine 47, respectively, which are the fifth and tenth amino acid residues, respectively, after removal of the prepro peptide. Because the regulation of glycosaminoglycan chain assembly is not fully understood and because of the in vivo existence of monoglycanated biglycan, mutant core proteins were stably expressed in human 293 and Chinese hamster ovary cells in which i) either one or both serine residues were converted into alanine or threonine residues, ii) the number of acidic amino acids N-terminal of the respective serine residues was altered, and iii) a hexapeptide was inserted between the mutated site 1 and the unaltered site 2. Labeling experiments with [(35)S]sulfate and [(35)S]methionine indicated that serine 42 was almost fully used as the glycosaminoglycan attachment site regardless of whether site 2 was available or not for chain assembly. In contrast, substitution of site 2 was greatly influenced by the presence or absence of serine 42, although additional mutations demonstrated a direct influence of the amino acid sequence between the two sites. When site 2 was not substituted with a glycosaminoglycan chain, there was also no assembly of the linkage region. These results indicate that xylosyltransferase is the rate-limiting enzyme in glycosaminoglycan chain assembly and implicate a cooperative effect on the xylosyl transfer to site 2 by xylosylation of site 1, which probably becomes manifest before the removal of the propeptide. It is shown additionally that biglycan expressed in 293 cells may still contain the propeptide sequence and may carry heparan sulfate chains as well as sulfated N-linked oligosaccharides.
Collapse
Affiliation(s)
- H Kresse
- Institute of Physiological Chemistry and Pathobiochemistry, University of Münster, D-48149 Münster, Germany.
| | | | | | | | | | | | | |
Collapse
|
70
|
Tapanadechopone P, Tumova S, Jiang X, Couchman JR. Epidermal transformation leads to increased perlecan synthesis with heparin-binding-growth-factor affinity. Biochem J 2001; 355:517-27. [PMID: 11284741 PMCID: PMC1221765 DOI: 10.1042/0264-6021:3550517] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Perlecan, a proteoglycan of basement membrane and extracellular matrices, has important roles in both normal biological and pathological processes. As a result of its ability to store and protect growth factors, perlecan may have crucial roles in tumour-cell growth and invasion. Since the biological functions of different types of glycosaminoglycan vary with cellular origin and structural modifications, we analysed the expression and biological functions of perlecan produced by a normal epidermal cell line (JB6) and its transformed counterpart (RT101). Expression of perlecan in tumorigenic cells was significantly increased in both mRNA and protein levels. JB6 perlecan was exclusively substituted with heparan sulphate, whereas that of RT101 contained some additional chondroitin sulphate. Detailed structural analysis of the heparan sulphate (HS) chains from perlecan of both cell types revealed that their overall sulphation and chain length were similar (approximately 60 kDa), but the HS chains of tumour-cell-derived perlecan were less sulphated. This resulted from reduced 2-O- and 6-O-sulphation, but not N-sulphation, and an increase in the proportion of unsulphated disaccharides. Despite this, the heparan sulphate of RT101- and JB6-derived perlecan bound fibroblast growth factor-1, -2, -4 and -7 and heparin-binding epidermal growth factor with similar affinity. Therefore abundant tumour-derived perlecan may support the angiogenic responses seen in vivo and be a key player in tumorigenesis.
Collapse
Affiliation(s)
- P Tapanadechopone
- Department of Cell Biology, Cell Adhesion and Matrix Research Center, University of Alabama at Birmingham, 201C Volker Hall, 1670 University Blvd., Birmingham, Alabama 35294-0019, USA
| | | | | | | |
Collapse
|
71
|
Chen RL, Lander AD. Mechanisms underlying preferential assembly of heparan sulfate on glypican-1. J Biol Chem 2001; 276:7507-17. [PMID: 11106655 DOI: 10.1074/jbc.m008283200] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Glypicans are major cell surface heparan sulfate proteoglycans, the structures of which are characterized by the presence of a cysteine-rich globular domain, a short glycosaminoglycan (GAG) attachment region, and a glycosylphosphatidylinositol membrane anchor. Despite strong evolutionary conservation of the globular domains of glypicans, no function has yet been attributed to them. By using a novel quantitative approach for assessing proteoglycan glycosylation, we show here that removal of the globular domain from rat glypican-1 converts the proteoglycan from one that bears approximately 90% heparan sulfate (HS) to one that bears approximately 90% chondroitin sulfate. Mutational analysis shows that sequences at least 70 amino acids away from the glypican-1 GAG attachment site are required for preferential HS assembly, although more nearby sequences also play a role. The effects of the glypican-1 globular domain on HS assembly could also be demonstrated by fusing this domain to sequences representing the GAG attachment sites of other proteoglycans or, surprisingly, simply by expressing the isolated globular domain in cells and analyzing effects either on an exogenously expressed glypican-1 GAG attachment domain or on endogenous proteoglycans. Quantitative analysis of the effect of the globular domain on GAG addition to proteoglycan core proteins suggested that preferential HS assembly is achieved, at least in part, through the inhibition of chondroitin sulfate assembly. These data identify the glypican-1 globular domain as a structural motif that potently influences GAG class determination and suggest that an important role of glypican globular domains is to ensure a high level of HS substitution of these proteoglycans.
Collapse
Affiliation(s)
- R L Chen
- Department of Developmental and Cell Biology and Developmental Biology Center, University of California, Irvine 92697, USA
| | | |
Collapse
|
72
|
Grill V, Sandrucci MA, Di Lenarda R, Cadenaro M, Narducci P, Bareggi R, Martelli AM. Biocompatibility evaluation of dental metal alloys in vitro: expression of extracellular matrix molecules and its relationship to cell proliferation rates. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH 2000; 52:479-87. [PMID: 11007615 DOI: 10.1002/1097-4636(20001205)52:3<479::aid-jbm5>3.0.co;2-x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The biocompatibility in vitro of dental biomaterials has been widely studied, with consideration of cell viability and cell proliferation rates. In the present study we evaluated the biocompatibility in vitro of three single-phase dental metal alloys, all provided by the same manufacturer. To this aim, we considered the percentage of proliferating cells revealed by 5-bromodeoxyuridine incorporation in human fibroblast cultures in the presence of these biomaterials, performing a short time test (72 h). These data were correlated with immunocytochemical expression of four molecules of the extracellular matrix, i.e., fibronectin, type I collagen, beta(1)-integrin subunit, and chondroitin sulfate, because the capability of cells to adhere to substrata is widely related to cell proliferation rates. Alloys presenting higher amounts of noble elements were more biocompatible even when they contained significant amount of both Ag and Cu. As regards the expression of the extracellular matrix molecules, the organization level of fibronectin in fibrils was correlated with higher cell proliferation rates, whereas no difference was detected for the expression of the other antigens. On these bases, we assume that expression of fibronectin could be a useful parameter in evaluation of biocompatibility in addition to cell proliferation capability.
Collapse
Affiliation(s)
- V Grill
- Department of Human Morphology, University of Trieste, Via Manzoni 16, I-34138 Trieste, Italy.
| | | | | | | | | | | | | |
Collapse
|
73
|
Friedrich MV, Schneider M, Timpl R, Baumgartner S. Perlecan domain V of Drosophila melanogaster. Sequence, recombinant analysis and tissue expression. EUROPEAN JOURNAL OF BIOCHEMISTRY 2000; 267:3149-59. [PMID: 10824099 DOI: 10.1046/j.1432-1327.2000.01337.x] [Citation(s) in RCA: 76] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The C-terminal domain V of the basement membrane proteoglycan perlecan was previously shown to play a major role in extracellular matrix and cell interactions. A homologous sequence of 708 amino-acid residues from Drosophila has now been shown to be 33% identical to mouse perlecan domain V. It consists of three laminin G-type (LG) and epidermal growth factor-like (EG) modules but lacks the EG3 module and a link region found in mammalian perlecans. Recombinant production of Drosophila perlecan domain V in mammalian cells yielded a 100-kDa protein which was folded into a linear array of three globular LG domains. Unlike the mouse counterpart, domain V from Drosophila was not modified by glycosaminoglycans and endogenous proteolysis, due to the absence of the link region. It showed moderate affinities for heparin and sulfatides but did not bind to chick alpha-dystroglycan or to various mammalian basement membrane proteins. A single RGD sequence in LG3 of Drosophila domain V was also incapable of mediating cell adhesion. Production of a proteoglycan form of perlecan (approximately 450 kDa) in one Drosophila cell line could be demonstrated by immunoblotting with antibodies against Drosophila domain V. A strong expression was also found by in situ hybridization and immunohistology at various stages of embryonic development and expression was localized to several basement membrane zones. This indicates, as for mammalian species, a distinct role of perlecan during Drosophila development.
Collapse
|
74
|
Abstract
Proteoglycans are widely expressed in animal cells. Interactions between negatively charged glycosaminoglycan chains and molecules such as growth factors are essential for differentiation of cells during development and maintenance of tissue organisation. We propose that glycosaminoglycan chains play a role in targeting of proteoglycans to their proper cellular or extracellular location. The variability seen in glycosaminoglycan chain structure from cell type to cell type, which is acquired by use of particular Ser-Gly sites in the protein core, might therefore be important for post-synthesis sorting. This links regulation of glycosaminoglycan synthesis to the post-Golgi fate of proteoglycans.
Collapse
Affiliation(s)
- K Prydz
- Department of Biochemistry and Institute for Nutrition Research, University of Oslo, Norway.
| | | |
Collapse
|
75
|
Tapanadechopone P, Hassell JR, Rigatti B, Couchman JR. Localization of glycosaminoglycan substitution sites on domain V of mouse perlecan. Biochem Biophys Res Commun 1999; 265:680-90. [PMID: 10600481 DOI: 10.1006/bbrc.1999.1714] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Perlecan, the predominant basement membrane proteoglycan, has previously been shown to contain glycosaminoglycans attached at serine residues, numbers 65, 71, and 76, in domain I. However, the C-terminal domains IV and V of this molecule may also be substituted with glycosaminoglycan chains, but the exact substitution sites were not identified. The amino acid sequence of mouse perlecan reveals many ser-gly sequences in these domains that are possible sites for glycosaminoglycan substitution. We expressed recombinant domain IV and/or V of mouse perlecan in COS-7 cells and analyzed glycosaminoglycan substitution. Both heparan sulfate and chondroitin sulfate chains could be detected on recombinant domain V. One site, ser-gly-glu (serine residue 3593), toward the C-terminal region of domain V is a substitution site for heparan sulfate. When this sequence was absent, chondroitin/dermatan sulfate substitution was deleted, and the likely site for this galactosaminoglycan substitution was ser-gly-ala-gly (serine residue 3250) on domain V.
Collapse
Affiliation(s)
- P Tapanadechopone
- Department of Cell Biology, Cell Adhesion and Matrix Research Center, University of Alabama at Birmingham, Birmingham, Alabama, 35294-0019, USA
| | | | | | | |
Collapse
|
76
|
Friedrich MV, Göhring W, Mörgelin M, Brancaccio A, David G, Timpl R. Structural basis of glycosaminoglycan modification and of heterotypic interactions of perlecan domain V. J Mol Biol 1999; 294:259-70. [PMID: 10556044 DOI: 10.1006/jmbi.1999.3259] [Citation(s) in RCA: 68] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The C-terminal perlecan domain V of about 90 kDa consists of laminin-type G domain modules (LG) (25 kDa) and epidermal growth factor-like modules (EG) (4 kDa) in the tandem arrangement LG1-EG1-EG2-LG2-EG3-EG4-LG3. Several shorter fragments have been prepared by recombinant production in mammalian cells and used to map the single glycosaminoglycan (GAG) substitution site and the binding of several carbohydrate and protein ligands. This identified a Ser3511 residue located in a short link region between EG4 and LG3 as being involved in GAG attachment. Electron microscopy provided evidence that the same substitution exists in tissue forms of perlecan. Heparan sulphate attached to this site was shown to bind to the alpha1LG4 module of laminin-1, indicating a role in basement membrane assembly and cell-matrix interactions. This site is also close to an Asn-Asp bond which is readily cleaved by an endogenous protease that depends on the presence of Asp and the LG2 module. A weak heparin binding site was shown to include the EG2 module, which contains five basic residues. Binding to sulphatides and the alpha-dystroglycan receptor was much stronger and required at least two LG modules. However, single LG modules appear to be sufficient for the interaction with the laminin-nidogen complex, while EG3-4 and some flanking regions are apparently involved in fibulin-2 binding. These observations indicate that a complex modular structure is required for domain V in order to provide a rich repertoire of potential biological functions.
Collapse
Affiliation(s)
- M V Friedrich
- Max-Planck-Institut für Biochemie, Martinsried, D-82152, Germany
| | | | | | | | | | | |
Collapse
|
77
|
Romarís M, Coomans C, Ceulemans H, Bruystens AM, Vekemans S, David G. Molecular polymorphism of the syndecans. Identification of a hypo-glycanated murine syndecan-1 splice variant. J Biol Chem 1999; 274:18667-74. [PMID: 10373479 DOI: 10.1074/jbc.274.26.18667] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
We have identified a cDNA that encodes a variant form of murine syndecan-1. The variant cDNA lacks the sequence corresponding to the first 132 nucleotides of the third exon of the syndecan-1 gene. The corresponding message is rare. The alternative splice respects the reading frame and deletes 44 amino acids from the protein, joining the S45GS47GT sequence to a variant immediate downstream context. This sequence context initiates with alanine instead of glycine as residue 50, reducing the number of SGXG sequence motifs in the protein from two to one. Expression of this variant syndecan-1 in Madin-Darby canine kidney or MOLT-4 cells yielded a recombinant proteoglycan with a reduced number and clustering of the heparan sulfate chains. Both the conversions of Ala50 and of Lys53 into glycine enhanced the heparan sulfate substitution of the variant protein. These findings support the concept that serine-glycine dipeptide signals for glycosaminoglycan/heparan sulfate synthesis depend on sequence context (Zhang, L., David, G., and Esko, J. D. (1995) J. Biol. Chem. 270, 27127-27135) and imply that alternative splicing mechanisms may in part control the molecular polymorphism of syndecan-1 and, therefore, the efficiency and versatility of this protein in its co-receptor functions.
Collapse
Affiliation(s)
- M Romarís
- Laboratory for Glycobiology and Developmental Genetics, Center for Human Genetics, University of Leuven and Flanders Interuniversity Institute for Biotechnology, B-3000 Leuven, Belgium
| | | | | | | | | | | |
Collapse
|
78
|
Chau CH, Shum DK, Chan YS, So KF. Heparan sulphates upregulate regeneration of transected sciatic nerves of adult guinea-pigs. Eur J Neurosci 1999; 11:1914-26. [PMID: 10336660 DOI: 10.1046/j.1460-9568.1999.00615.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The increased content of soluble glycosaminoglycan-containing forms in sciatic nerves during recovery from crush injury [Shum & Chau (1996) J. Neurosci. Res., 46, 465] suggests that the glycosaminoglycans modulate the environment for post-traumatic tissue remodelling and axonal regrowth. To test this, defined amounts of soluble heparan sulphates from bovine kidney or guinea-pig nerve were introduced into the regenerating environment via silicone conduits that bridged 8-mm gaps of transected sciatic nerves of adult guinea-pigs. Controls were bridged using the phosphate-buffered saline (PBS) vehicle or a chondroition sulphate preparation from whale cartilage. After timed periods of recovery, the animals were assessed for electromyographic signals at the target gastrocnemius muscle to determine the conduction velocity across the bridged nerve. Sections of the bridge were also histologically examined for nerve fibres. Transected sciatic nerves bridged with heparan sulphates or chondroitin sulphate showed earlier stimulated myelination of axons (week 5-6) than PBS-bridged nerves (week 9). Initial electromyographic indication of reconnection with the target was at week 9 post-transection. In the course of 20 weeks, transected sections of the bridge indicated similar numbers of unmyelinated axons irrespective of bridge material, but distinctly higher numbers of myelinated axons in heparan sulphate-bridged nerves than either PBS- or chondroitin sulphate-bridged nerves. At the end of the same period, heparan sulphate-bridged nerves resumed normal conduction velocities, but both PBS- and chondroitin sulphate-bridged nerves remained at 50% of that of the intact contralateral nerves. These results are the first to demonstrate that supplementation of soluble heparan sulphate to the fluid regenerative neural environment can restore functional, axonal reconnection of the severed nerve with the target muscle.
Collapse
Affiliation(s)
- C H Chau
- Department of Biochemistry, Faculty of Medicine, The University of Hong Kong, Hong Kong, China
| | | | | | | |
Collapse
|
79
|
Slater M, Murphy CR. Chondroitin sulphate and heparan sulfate proteoglycan are sequentially expressed in the uterine extracellular matrix during early pregnancy in the rat. Matrix Biol 1999; 18:125-31. [PMID: 10372552 DOI: 10.1016/s0945-053x(99)00006-2] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Chondroitin sulfate proteoglycan (CSPG) and heparan sulfate proteoglycan (HSPG) are extracellular matrix proteins that regulate cell adhesion, growth, migration, differentiation and gene expression in many systems. In this study, stromal CSPG label was intense within 10 microm of the uterine lumen. From that distance to the myometrium, CSPG was de-expressed. From the time of implantation on Day 6, this pattern was reversed. CSPG was de-expressed from the uterine epithelium to a distance of approximately 10 microm from the uterine lumen. From that region to the myometrium, labeling was homogeneously intense. This finding suggests that CSPG may inhibit attachment and implantation. Heparan sulfate core proteoglycan (perlecan) was increasingly expressed in the uterine epithelium from the time of implantation, commencing in the basement membrane on Day 6 and extending to the apical epithelium and lateral plasma membranes by Day 7. Perlecan thus appears to facilitate trophoblast attachment and implantation. We propose that attachment and implantation is regulated, at least in part, by the selective and sequential expression of CSPG and perlecan.
Collapse
Affiliation(s)
- M Slater
- Department of Anatomy and Histology F13, The University of Sydney, NSW, Australia
| | | |
Collapse
|
80
|
Whitelock JM, Graham LD, Melrose J, Murdoch AD, Iozzo RV, Underwood PA. Human perlecan immunopurified from different endothelial cell sources has different adhesive properties for vascular cells. Matrix Biol 1999; 18:163-78. [PMID: 10372557 DOI: 10.1016/s0945-053x(99)00014-1] [Citation(s) in RCA: 110] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Perlecan, a major heparan sulfate proteoglycan of vascularized tissues, was immunopurified from media conditioned by human endothelial cells of both arterial and venous origin. The heparan sulfate moiety of perlecan from cultured arterial cells differed in amount and/or composition from that produced by a transformed cell line of venous origin. Both forms of perlecan bound basic fibroblast growth factor with Kd approximately 70 nM. In ELISA experiments, perlecan and its protein core bound to various extracellular matrix components in a manner that was strongly influenced by the format of the assay. Human vascular smooth muscle cells and human endothelial cells adhered to perlecan-coated surfaces, and both cell types adhered better to the venous cell-derived than to the arterial cell-derived perlecan. Removal of the heparan sulfate chains abolished this difference and increased the ability of both types of perlecan to adhere vascular cells. Denaturation of perlecan and its protein core also rendered each of them more adhesive, indicating the presence of conformation-independent adhesion determinants in the polypeptide sequence. Their location was investigated using recombinant perlecan domains. Overall, our results represent the first demonstration of human perlecan acting as an adhesive molecule for human vascular cells and suggest that it may play a role in vascular wound healing.
Collapse
Affiliation(s)
- J M Whitelock
- Co-operative Research Center for Cardiac Technology, North Ryde, NSW, Australia.
| | | | | | | | | | | |
Collapse
|
81
|
Graham LD, Whitelock JM, Underwood PA. Expression of human perlecan domain I as a recombinant heparan sulfate proteoglycan with 20-kDa glycosaminoglycan chains. Biochem Biophys Res Commun 1999; 256:542-8. [PMID: 10080934 DOI: 10.1006/bbrc.1999.0377] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Recombinant forms of human perlecan domain I were secreted as proteoglycans by stably transfected human 293 cells. A recombinant domain I-only proteoglycan spanned the 95- to 265-kDa region in SDS-PAGE and appeared to be 160 kDa in denaturing gel filtration. Its glycosaminoglycan (GAG) content was approximately 67% heparan sulfate, and its average GAG chain size of 20 kDa suggested that the true molecular mass of the proteoglycan was 90 kDa. Domain I with enhanced green fluorescent protein fused to its C-terminus had an apparent molecular mass of 210-220 kDa and contained approximately 100% heparan sulfate. Its average GAG chain size (also 20 kDa) suggested a true molecular mass of 117 kDa for this proteoglycan. Its sulfate content of 53-77 mol SO2-4 per mole of protein indicated the presence of one sulfate group per 4-7 GAG sugar residues.
Collapse
Affiliation(s)
- L D Graham
- CSIRO Molecular Science, Sydney Laboratory, North Ryde, New South Wales, 1670, Australia.
| | | | | |
Collapse
|
82
|
Brown CT, Nugent MA, Lau FW, Trinkaus-Randall V. Characterization of proteoglycans synthesized by cultured corneal fibroblasts in response to transforming growth factor beta and fetal calf serum. J Biol Chem 1999; 274:7111-9. [PMID: 10066769 DOI: 10.1074/jbc.274.11.7111] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
A culture system was developed to analyze the relationship between proteoglycans and growth factors during corneal injury. Specifically, the effects of transforming growth factor beta-1 (TGF-beta1) and fetal calf serum on proteoglycan synthesis in corneal fibroblasts were examined. Glycosaminoglycan synthesis and sulfation were determined using selective polysaccharidases. Proteoglycan core proteins were analyzed using gel electrophoresis and Western blotting. Cells cultured in 10% dialyzed fetal calf serum exhibited decreased synthesis of more highly sulfated chondroitin sulfate and heparan sulfate compared with cells cultured in 1% dialyzed fetal calf serum. The amount and sulfation of the glycosaminoglycans was not significantly influenced by TGF-beta1. The major proteoglycan species secreted into the media were decorin and perlecan. Decorin was glycanated with chondroitin sulfate. Perlecan was linked to either chondroitin sulfate, heparan sulfate, or both chondroitin sulfate and heparan sulfate. Decorin synthesis was reduced by either TGF-beta1 or serum. At early time points, both TGF-beta1 and serum induced substantial increases in perlecan bearing chondroitin sulfate and/or heparan sulfate chains. In contrast, after extended periods in culture, the amount of perlecan bearing heparan sulfate chains was unaffected by TGF-beta1 and decreased by serum. The levels of perlecan bearing chondroitin sulfate chains were elevated with TGF-beta1 treatment and were decreased with serum. Because both decorin and perlecan bind growth factors and are proposed to modulate their activity, changes in the expression of either of these proteoglycans could substantially affect the cellular response to injury.
Collapse
Affiliation(s)
- C T Brown
- Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts 02118, USA
| | | | | | | |
Collapse
|
83
|
Hopf M, Göhring W, Kohfeldt E, Yamada Y, Timpl R. Recombinant domain IV of perlecan binds to nidogens, laminin-nidogen complex, fibronectin, fibulin-2 and heparin. EUROPEAN JOURNAL OF BIOCHEMISTRY 1999; 259:917-25. [PMID: 10092882 DOI: 10.1046/j.1432-1327.1999.00127.x] [Citation(s) in RCA: 126] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Domain IV of mouse perlecan, which consists of 14 immunoglobulin superfamily (IG) modules, was prepared from recombinant human cell culture medium in the form of two fragments, IV-1 (IG2-9, 100 kDa) and IV-2 (IG10-15, 66 kDa). Both fragments bound to a heparin column, being eluted at ionic strengths either below (IV-2) or above (IV-1) physiological level, and could thus be readily purified. Electron microscopy demonstrated an elongated shape (20-25 nm), and folding into a native structure was indicated by immunological assay and CD spectroscopy. Solid-phase and surface plasmon resonance assays demonstrated strong binding of fragment IV-1 to fibronectin, nidogen-1, nidogen-2 and the laminin-1-nidogen-1 complex, with Kd values in the range 4-17 nM. The latter binding apparently occurs through nidogen-1, as shown by the formation of ternary complexes. Only moderate binding was observed for fibulin-2 and collagen IV and none for fibulin-1 and BM-40. Fragment IV-2 showed a more restricted pattern of binding, with only weaker binding to fibronectin and fibulin-2. None of these activities could be demonstrated for recombinant fragments corresponding to the N-terminal perlecan domains I to III. This indicates a special role for domain IV in the integration of perlecan into basement membranes and other extracellular structures via protein-protein interactions.
Collapse
Affiliation(s)
- M Hopf
- Max-Planck-Institut für Biochemie, Martinsried, Germany
| | | | | | | | | |
Collapse
|
84
|
Langford JK, Stanley MJ, Cao D, Sanderson RD. Multiple heparan sulfate chains are required for optimal syndecan-1 function. J Biol Chem 1998; 273:29965-71. [PMID: 9792716 DOI: 10.1074/jbc.273.45.29965] [Citation(s) in RCA: 75] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Syndecans have three highly conserved sites available for heparan sulfate attachment. To determine if all three sites are required for normal function, a series of mutated syndecans having two, one, or no heparan sulfate chains were expressed in ARH-77 cells. Previously, we demonstrated that expression of wild-type syndecan-1 on these myeloma cells mediates cell-matrix and cell-cell adhesion and inhibits cell invasion into collagen gels. Here we show that to optimally mediate each of these activities, all three sites of heparan sulfate attachment are required. Generally, an increasing loss of syndecan-1 function occurs as the number of heparan sulfate attachment sites decreases. This loss of function is not the result of a decrease in either the total amount of cell surface heparan sulfate or syndecan-1 core protein. In regard to cell invasion, cells expressing syndecan-1 bearing a single heparan sulfate attachment site exhibit a hierarchy of function based upon the position of the site within the core protein; the presence of an available attachment site at serine 47 confers the greatest level of activity, while serine 37 contributes little to syndecan-1 function. However, when all three heparan sulfate chains are present, significantly greater biological activity is observed than is predicted by the sum of the activities occurring when the chains act individually. This synergy provides a functional basis for the evolutionary conservation of the three heparan sulfate attachment sites on syndecans and supports the idea that molecular heterogeneity, which is characteristic of proteoglycans, contributes to their functional diversity.
Collapse
Affiliation(s)
- J K Langford
- Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
| | | | | | | |
Collapse
|
85
|
Abstract
The proteoglycan superfamily now contains more than 30 full-time molecules that fulfill a variety of biological functions. Proteoglycans act as tissue organizers, influence cell growth and the maturation of specialized tissues, play a role as biological filters and modulate growth-factor activities, regulate collagen fibrillogenesis and skin tensile strength, affect tumor cell growth and invasion, and influence corneal transparency and neurite outgrowth. Additional roles, derived from studies of mutant animals, indicate that certain proteoglycans are essential to life whereas others might be redundant. The review focuses on the most recent genetic and molecular biological studies of the matrix proteoglycans, broadly defined as proteoglycans secreted into the pericellular matrix. Special emphasis is placed on the molecular organization of the protein core, the utilization of protein modules, the gene structure and transcriptional control, and the functional roles of the various proteoglycans. When possible, proteoglycans have been grouped into distinct gene families and subfamilies offering a simplified nomenclature based on their protein core design. The structure-function relationship of some paradigmatic proteoglycans is discussed in depth and novel aspects of their biology are examined.
Collapse
Affiliation(s)
- R V Iozzo
- Department of Pathology, Anatomy and Cell Biology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107-6799, USA.
| |
Collapse
|
86
|
Sasaki T, Costell M, Mann K, Timpl R. Inhibition of glycosaminoglycan modification of perlecan domain I by site-directed mutagenesis changes protease sensitivity and laminin-1 binding activity. FEBS Lett 1998; 435:169-72. [PMID: 9762901 DOI: 10.1016/s0014-5793(98)01063-1] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
Glycosaminoglycan attachment to perlecan domain I (173 residues) was completely prevented by site-directed mutagenesis of Ser-65, Ser-71 and Ser-76 as shown by recombinant production in mammalian cells. This did not interfere with the proper folding of the domain's SEA module but enhanced its sensitivity to neutral proteases. Lack of substitution also abolished binding to the two major heparin binding sites of laminin-1.
Collapse
Affiliation(s)
- T Sasaki
- Max-Planck-Institut für Biochemie, Martinsried, Germany
| | | | | | | |
Collapse
|
87
|
Doege K, Chen X, Cornuet PK, Hassell J. Non-glycosaminoglycan bearing domains of perlecan and aggrecan influence the utilization of sites for heparan and chondroitin sulfate synthesis. Matrix Biol 1997; 16:211-21. [PMID: 9402011 DOI: 10.1016/s0945-053x(97)90010-x] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Perlecan and aggrecan are proteoglycans that receive primarily heparan sulfate and chondroitin sulfate side chains, respectively. Their large multidomained core proteins have little or no homology to each other and their glycosaminoglycan (GAG) attachment sites are restricted to certain domains only. We examined the involvement of the non-GAG bearing domains in designating the GAG type added to the GAG attachment domain by preparing cDNA constructs that expressed perlecan/aggrecan chimeras as recombinant products in COS-7 cells and then determining the size and GAG composition of the recombinant products. The results showed that domain I of perlecan receives primarily (73-81%) heparan sulfate when coupled with domain II and III of perlecan, but when coupled with the G3 domain of aggrecan, it receives primarily (59-63%) chondroitin sulfate. Furthermore, the chondroitin sulfate attachment region of aggrecan received GAG side chains more readily when coupled to the G3 domain of aggrecan than when coupled to domains II and III of perlecan. The GAG side chains on all these recombinant products were small and similar in size. These findings indicate that the utilization of attachment sites for heparan and chondroitin sulfate or the sulfation of these GAGs can be influenced, in part, by non-GAG bearing domains.
Collapse
Affiliation(s)
- K Doege
- Shriners Hospital for Crippled Children, Research Unit, Portland, Oregon, USA
| | | | | | | |
Collapse
|
88
|
Abstract
Perlecan is a modular heparan sulfate proteoglycan that is an intrinsic constituent of all basement membranes and extracellular matrices. Because of its strategic position and unique structure, perlecan has been implicated in modulating the activity of various growth factors required for normal development and tissue homeostasis. To gain insights into the potential function of perlecan in vivo, we examined the spatiotemporal distribution of its mRNA and protein core during murine embryogenesis. We utilized a new affinity-purified antibody that recognizes specifically the protein core of perlecan together with an in situ RT-PCR approach to perform a systematic analysis of perlecan expression and deposition during murine ontogeny. Perlecan appeared early (E10.5) in tissues of vasculogenesis including heart, pericardium, and major blood vessels. Its early expression coincided with the development of the cardiovascular system. Subsequently (E11-13), the greatest deposition of perlecan occurred within the developing cartilage, especially the cartilage undergoing endochondral ossification, where it remained elevated throughout all the developmental stages, and up to adulthood. Interestingly, the mRNA levels of perlecan were always higher in all the vascularized tissues, principally within endothelial cells, while chondrocytes displayed relatively low mRNA levels. This suggests a higher biosynthesis and turnover rates in the blood vessels vis-à-vis those of cartilaginous and other mesenchymal tissues. During later stages of development (E13-17.5) perlecan mRNA levels progressively increased and its expression correlated with the onset of tissue differentiation of various parenchymal organs including the developing kidneys, lungs, liver, spleen, and gastrointestinal tract. The central nervous system showed no perlecan expression with the exception of the calvaria and choroid plexus. Collectively, the results indicate that perlecan may play crucial roles not only in vasculogenesis but also in the maturation and maintenance of differentiated tissues, including cartilage.
Collapse
Affiliation(s)
- M Handler
- Department of Pathology, Anatomy and Cell Biology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
| | | | | |
Collapse
|
89
|
Rosenberg RD, Shworak NW, Liu J, Schwartz JJ, Zhang L. Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated? J Clin Invest 1997; 99:2062-70. [PMID: 9151776 PMCID: PMC508034 DOI: 10.1172/jci119377] [Citation(s) in RCA: 239] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Affiliation(s)
- R D Rosenberg
- Department of Biology, Massachusetts Institute of Technology, Cambridge 02139, USA.
| | | | | | | | | |
Collapse
|